Positive correlation between chymase-like angiotensin II -forming activity in mononuclear cells and serum cholesterol level

Journal of Cardiology

Volumn 50, Issue 5, 2007, Pages 291-298

  Murakami, Kinshiro ^a   Uehara, Yoshinari ^a   Abe, Satomi ^a,b   Inoue, Yukiko ^b   Ideishi, Munehito ^a   Saku, Keijiro ^a   Urata, Hidenori ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Angiotensin II; Atherosclerosis; Cholesterol; Hypertension; Leukocyte

Indexed keywords

ANGIOTENSIN II; CHOLESTEROL; CHYMASE;

ARTICLE; ATHEROSCLEROSIS; BLOOD; BLOOD SAMPLING; CARDIOVASCULAR RISK; CELL FRACTIONATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HYPERTENSION; ISCHEMIC HEART DISEASE; MONONUCLEAR CELL; POLYMORPHONUCLEAR CELL; ARTERIOSCLEROSIS; BIOSYNTHESIS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; RISK FACTOR; SMOKING;

ANGIOTENSIN II; ARTERIOSCLEROSIS; CHOLESTEROL; CHYMASES; HUMANS; HYPERTENSION; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 38549150927     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Schiffrin EL, Deng LY, Sventek P, Day R: Enhanced expression of endothelin-I gene in resistance arteries in severe human essential hypertension. J Hyperten 1997; 15: 57-63
2. 1 receptor subtype. Circ Res 1993; 73: 413-423
3. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
4. 2 in angiotensin II - induced vascular hypertrophy. Hypertension 1998; 32: 488-495
5. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK: p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II -induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-23321
6. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK: Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274: 22699-22704
7. Arakawa K: Serine protease angiotensin II systems. J Hypertens Suppl 1996; 14: S3-S7
8. Urata H, Hoffmann S, Ganten D: Tissue angiotensin II system in the human heart. Eur Heart J 1994; 15 (Suppl D): 68-78
9. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K: Differences in tissue angiotensin II -forming pathways by species and organs in vitro. Hypertension 1998; 32: 514-520
10. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, Ideishi M, Arakawa K: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-1405
11. Uehara Y, Urata H, Sasaguri M, Ideishi M, Sakata N, Tashiro T, Kimura M, Arakawa K: Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 2000; 35: 55-60
12. Boyum A: Separation of white blood cells. Nature 1964; 204: 793-794
13. Ferrante A, Thong YH: Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method. J Immunol Methods 1980; 36: 109-117
14. Ihara M, Urata H, Shirai K, Ideishi M, Hoshino F, Suzumiya J, Kikuchi M, Arakawa K: High cardiac angiotensin- II -forming activity in infarcted and non-infarcted human myocardium. Cardiology 2000; 94: 247-253
15. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M: Marked species-difference in the vascular angiotensin II -forming pathways: Humans versus rodents. Jpn J Pharmacol 1993; 62: 207-210
16. Tachmes L, Fernandez RJ, Sackner MA: Hemodynamic effects of smoking cigarettes of high and low nicotine content. Chest 1978; 74: 243-246
17. Koga T, Urata H, Inoue Y, Hoshino T, Okamoto T, Matsunaga A, Suzuki M, Miyazaki J, Ideishi M, Arakawa K, Saku K: Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy. Hypertens Res 2003; 26: 759-768
18. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell'Italia LJ, Feneley MP, Graham RM, Husain A: Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 2004; 114: 112-120
19. Smithies O: Theodore Cooper Memorial Lecture: A mouse view of hypertension. Hypertension 1997; 30: 1318-1324
20. Hahn AW, Jonas U, Bühler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178-180
21. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K: Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II -induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: e174-e178
22. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS: Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-825
23. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117
24. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K: Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002; 55: 870-876
25. Lindholm LH, Hansson L, Dahlöf B, Ekbom T, Hedner T, De Faire U, Scherstén B, Wester PO: The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): A progress report. Blood Press 1996; 5: 300-304
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENALL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
27. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002; 106: 672-678
28. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603
29. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652